Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Matheson

Showing results (301-310 of 305) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 305 results.
Nature Communications|December 15, 2020
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case reportMatthew S Buckland, James B Galloway, Caoimhe Nic Fhogartaigh, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
Nature|February 1, 2022
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicityBo Meng, Adam Abdullahi, Isabella A T M Ferreira, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 31

Showing results (301-310 of 305) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 305 results.
Nature Communications|December 15, 2020
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case reportMatthew S Buckland, James B Galloway, Caoimhe Nic Fhogartaigh, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
Nature|February 1, 2022
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicityBo Meng, Adam Abdullahi, Isabella A T M Ferreira, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 31